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ABSTRACT 
 
Purpose. Hepatocellular carcinoma (HCC) exhibits a variable response to Yttrium 90 (
90
Y) 
radioembolization. Imaging response assessment criteria in transarterial therapies appear to 
display an imperfect correlation with survival. We sought to evaluate whether specific 
imaging patterns of HCC at presentation may predict tumor response. Additionally, we 
assessed specific tumor features and their relation with overall survival (OS) and 
progression-free survival (PFS). 
Methods. A retrospective cohort of 16 patients with HCC diagnosis selected for 
90
Y 
radioembolization was reviewed. Computed tomography (CT) images before and after 
treatment were assessed for specific tumor features. Tumor response was graded according 
to mRECIST, EASL and Choi criteria. HCC characteristics associated with OS and PFS 
were documented. 
Results. Sixteen patients were included in the study, with a median follow-up of 26.2 months. 
The median overall and post-radioembolization survival was 37.5 months and 22.6 months 
respectively. Tumor size (p 0.046) and number of tumor nodules (p 0.029) recorded at 
baseline significantly changed with radioembolization. No complete imagiological responders 
were recorded according to any criteria. Both mRECIST and EASL criteria reported a 
majority of stable disease (61.5% and 53.8%, respectively). Choi response criteria classified 
most patients as responders (69.2%). Radiologic tumor response according to imaging 
assessment criteria exhibited no relation with patient survival.  
Conclusions. HCC imaging features at presentation may predict tumor response to 
radioembolization. Prospective trials with larger cohorts are necessary in order to confirm 
and further extend the assessment of radioembolization response and related predictors and 
to determine tumor characteristics related to PFS and OS.  
 
KEYWORDS: Hepatocellular carcinoma; Yttrium 90; Radioembolization; mRECIST; Choi 
criteria; EASL 
1. Introduction 
Liver cancer positions as the sixth most prevalent neoplasm globally. Poor prognosis at 
presentation places it as the third leading cause of cancer-related mortality, accountable for 696,000 
deaths annually. [1] 
Treatment management of hepatocellular carcinoma (HCC) includes potentially curative, 
palliative, and symptomatic approaches. [2]  Only ten percent of HCC patients will be eligible for 
curative therapies [3] , thus, targeted therapies have been emerging.
 
[4] Recently, Yttrium 90 (
90
Y) 
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microspheres were approved for liver cancer [5, 6] and acknowledged as a treatment option for 
HCC in selected cases [7-10].  
Indications for 
90
Y radioembolization continue to expand [8, 11, 12] due to its feasibility in the 
presence of portal vein thrombosis[13, 14] and favorable safety profile in the cirrhotic liver with 
evidence of  preserved liver function[15]. Still, consensual selection criteria for radioembolization 
in HCC are yet to be established.   
This transarterial therapy associates a marginal embolic effect and cytotoxicity of radiation, 
frequently inducing necrosis without significant tumor size variation. [16]
 
 Therefore, response 
assessment criteria which rely on tumor size shrinkage solely to state response to treatment may be 
inadequate. [17, 18]  
HCC response to radioembolization with 
90
Y occurs in varying degrees with most series 
reporting response rates of twenty five to fifty percent. [19] Disparity in the magnitude of tumor 
response may reflect differences in tumor imaging patterns prior to 
90
Y therapy. 
Imaging response has shown the ability to predict survival benefit following locoregional 
therapies. [20] Still, radioembolization impact on survival varies widely with a reported median 
overall survival of 12.8 months.  Median time-to-progression ranges from 7.9-10.0 months and 
from 11.8-15.5 months for patients without portal vein invasion. [20, 21]. 
The aim of our study was to recognize specific imaging patterns of HCC at presentation that 
may predict tumor response to 
90
Y radioembolization. Futhermore, we sought to investigate the 
relation of tumor response predictors with progression-free-survival (PFS) and overall survival 
(OS). 
2. Patients and Methods 
2.1.  Patient selection 
This retrospective review included sixteen patients with hepatocellular carcinoma submitted 
to 
90
Y radioembolization at Centro Hospitalar de São João, EPE. of Porto, Portugal from 2010 
to 2013. 
Inclusion criteria consisted of: 1) diagnosis of hepatocellular carcinoma according to EASL-
EORTC practice guidelines
 
criteria [22] and 2) radioembolization treatment using 
90
Y glass 
microspheres. 
2.2. Clinical characteristics 
Clinical data collected comprised age, gender, etiology of HCC, total bilirubin (mg/dl), 
albumin (g/L), ALT (U/L), creatinine (mg/dL) and alpha-fetoprotein (ng/mL) levels, Child Pugh 
status and evidence of cirrhosis. Supplementary data included target liver region, target liver 
volume and number of radioembolization treatments. 
2.3. 90Y Glass Micropheres radioembolization 
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Prior to 
90
Y injection, a digital substraction angiography was obtained for vascular anatomy 
documentation and hepatofugal vessels were coil-embolized. Simultaneously, a hepatic arterial 
perfusion scintigraphy with SPECT-CT images using technetium-99m labeled macroaggregated 
albumin (MAA-Tc-99m) was also performed to simulate the microspheres distribution and 
identify potential pulmonary or extra-hepatic abdominal shunting. Patients with a pulmonary 
shunt determining lung exposure superior to 30 Gy per treatment, or cumulative lung exposure 
superior to 50 Gy, were excluded. 
Radioembolization treatment was executed by percutaneous transarterial injection of glass 
micropheres loaded with 
90
Y (TheraSphere®, MDS Nordion, Ottawa, Ontario, Canada), through 
the hepatic artery.glass micropheres loaded with 
90
Y, through the hepatic artery. 
Radiation dose was individually determined for each patient according to liver volumetric 
calculation. Median calculated radiation dose was 126.5 GBq (range, 114.0–151.0). 
Bremsstrahlung scans obtained post- radioembolization procedure verified the adequate 
distribution of the 
90
Y microspheres to the tumor lesions. 
 
2.4. Computed Tomography Assessment 
Abdominal triphasic computed tomography (CT) scans of the liver were obtained at two 
distinct time points, baseline and post-radioembolization. 
A radiologist who was blind to the patient outcome reviewed all CT images for the 
following tumor features (1) number of lesions; (2) bidimensional tumor size; (3) median tumor 
attenuation (density in Hounsfield units [HU]); (4) tumor margins (well or poorly defined); (5) 
arterial enhancement (hyperenhancing or hypoenhancing); (6) tumor enhancement pattern 
(homogenous or heterogeneous); (7) extent of tumor necrosis (≤50%; or >50%).  
Images were also reviewed for the presence of portal venous thrombosis, ascites and 
pathological lymph nodes.  
 
2.5. Statistical Analysis and Response Assessment 
Tumor response to radioembolization was evaluated according to mRECIST [23], 
EASL[24] and Choi[25] imaging response assessment criteria. 
Categorical variables were reported as number (%) and measured data was reported as 
median (range, minimum to maximum).  
Differences in baseline tumor features and after 
90
Y radioembolization were compared using 
Fisher exact test (categorical variables) and Wilcoxon sign test (continuous variables).  
Survival among strata was recorded using Kaplan-Meier curves and compared through a 
log-rank test. 
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The primary endpoint was PFS described as the time, measured in months, from 
radioembolization treatment until CT documentation of disease progression. The secondary 
endpoint was OS, defined as time between HCC diagnosis and date of death.  
All statistical analysis was executed with SPSS 22.0 software (SPSS Inc., Chicago, Illinois, 
USA) and statistical significance was determined at a p value of < 0.05. 
 
3. Results 
Patients included in the study were predominantly male (75.0%) with a median age of 63.5 
years (range 54 – 74 years). The most frequent etiologies were HBV infection and alcohol 
consumption (25.0%). The majority of patients exhibited liver cirrhosis (81.2%) and had Child-
Pugh stage A liver dysfunction (68.8%). 
Eleven patients were submitted to one radioembolization session while five patients were 
submitted to 2 sessions. 
Four patients were subjected to multimodality therapy, two patients received transarterial 
chemoembolization prior to radioembolization and two patients were submitted to hepatic 
resection after radioembolization.  
Median follow-up was 26.18 months (range 10-60 months), with a total of 9 death events 
recorded. The median overall and post-radioembolization survival was 37.5 months (CI, 24.7-
50.2) and 22.6 months (CI, 17.2-28.1), respectively. 
Table 1 summarizes the clinicopathological features of the patients submitted to 
radioembolization. 
Most patients (53.8%) had less than 5 tumor nodules, even though a considerable number of 
patients had multifocal disease, with two cases of innumerable tumor lesions. 
Of the 16 patients with HCC diagnosis proposed to 
90
Y radioembolization treatment, 13 had 
adequate pre and post RE imaging and three patients were excluded for lack of follow-up 
imaging. 
The median baseline target lesion longest axis was 66.0 mm (15.0-99.0 mm), and median 
tumor attenuation was 84.0 HU (0-133 HU). Most tumors presented a heterogenous 
hyperenhancing pattern (92.3%), less than 50% tumor necrosis (92.3%) and poorly defined 
margins (69.2%). 
 The median hepatopulmonary shunt fraction estimated by MAA-Tc-99m scintigraphy 
before radioembolization was 7.1% and the median target liver volume was 834.0. Median 
90
Y 
activity of microspheres administered to the patient was 2.3 GBq (range, 1.2–3.6).  
No complete imagiological responders were recorded according to any criteria. Both 
mRECIST and EASL criteria reported a majority of stable disease (61.5% and 53.8%, 
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respectively). Partial response was documented according to mRECIST and EASL in 3 and 1 
patients, respectively. Choi response criteria classified most patients as responders (69.2%). 
The comparison of the imaging features of the follow-up CT scan obtained a median of 2.6 
months after treatment to the baseline CT scan are summarized in table 2. This analysis 
demonstrated significant difference in pre and post-radioembolization tumor size (p 0.046) and 
number of lesions (p 0.029), as well as a trend towards lower tumor attenuation (p 0.092) 
following radioembolization. 
The median survival, as previously refered, was 37.5 months (95% CI, 24.7-50.2) and was 
not significantly altered by patient’s clinical status, age, gender or etiology of HCC. 
There were no clinical characteristics or tumor features linked with improved median 
survival. Overall survival was diminished in patients with Child-Pugh B liver dysfunction(18.0 
months), and bilirubin levels superior to 1.5 mg/dl (27.6 months) compared to those with Child-
Pugh status A (60.0 months) and bilirubin level inferior to 1.5 mg/dl (44.8 months), although, it 
did not reach statistical significance (p 0.381 and 0.285 respectively). 
Survival according to baseline characteristics is displayed in Table 3. 
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4. Discussion 
Response assessment criteria for HCC seem to underestimate tumor response when applied 
to selective transarterial therapies such as radioembolization. Thus, investigation on alternative 
response criteria addressing these limitations is starting to emerge [26]. Choi criteria, initially 
designed for evaluation of treatment response of GIST to imatinib mesylate, was proposed as an 
appropriate predictor of  HCC response to 
90
Y radioembolization [27]   
In this study, we present the radiologic tumor features linked with response.This analysis 
might help support the recognition, at presentation, of HCC patients with predictable benefit 
from 
90
Y radioembolization. 
Our investigation of the imaging features related with radioembolization concluded both 
tumor size (p 0.046) and number of lesions (p 0.029) significantly decreased with treatment, 
establishing the importance of monitoring these parameters. Previous clinical studies 
corroborate the finding of radioembolization´s  ability to diminish tumor burden among patients 
with HCC [28].  
In our perspective, other tumor features, such as tumor attenuation, the presence of ascites 
and presence of PVT should be addressed in future studies considering that our results showed 
differences, though, these were not statistically significant.   
Mean overall survival was not considerably altered by patient’s age, gender or etiology of 
HCC recommending that these factors should not be applied as selection criteria. 
Mean overall survival was related to Child-Pugh status and bilirubin level, though the 
results were not statistically significant. 
The evaluation of response criteria relation with survival or PFS did not reveal significant 
results with any of the response criteria assessed.  
Our study is limited by its retrospective design and reduced number of patients. 
Additionally, CT scanning assessment could have been inconsistent due to subjectivity in 
interpretation and technical discrepancies. Variation in the follow up CT time after 
radioembolization treatment mirrors standard clinical practice circumstances.  
In summary, tumor features of HCC at presentation in association with patient clinical 
status may predict response to radioembolization. Prospective trials with larger cohorts are 
necessary in order to confirm and further extend the assessment of radioembolization response 
and related predictors and to determine tumor characteristics related to PFS and OS.  
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Table 1. Patient and Tumor Characteristics at Baseline and 
Radioembolization Parameters* 
Characteristics Values 
Age, median (range) 63.5 (54 to 74) 
Gender, no. (%) 
Male 
Female 
 
12 (75.0) 
4 (25.0) 
Etiology, no. (%) 
HBV 
HCV 
HBV+HCV 
Alcohol 
HCV+alcohol 
Hemocromatosis 
Not determined 
 
4 (25.0) 
3 (18.7) 
1 (6.3) 
4 (25.0) 
1 (6.3) 
1 (6.3) 
2 (12.5) 
Child-Pugh, no. (%) 
A 
B 
 
11 (68,8) 
5 (31.2) 
Albumin (g/L),  median (range) 35.5 (30.6 to 43.2) 
Alpha-Phetoprotein (ng/mL),  
median (range) 
21.5 (2.9 to 2554.0) 
ALT (U/L),  median (range) 61.0 (28.0 to 145.0) 
Creatinine (mg/dL),  median (range) 0.9 (0.5 to 10.6) 
Total billirubin (mg/dL),  median 
(range) 
0.8 (0.4 to 2.4) 
Presence of cirrhosis, no. (%) 13 (81.2) 
Number of treatments, no. (%) 
1 
2 
11 (68.8) 
5 (31.2) 
Y
90 
Activity administered, GBq, 
median (range) 
2.3 (1.2 to 3.6) 
Target Liver Volume, cc, median 
(range) 
834.0 (360.0 to 1381.9) 
Hepatopulmonary shunt fraction,  
median (range) 
7.1 (1.9 to 21.9) 
Abbreviations:  HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine 
aminotransferase 
*N=16 
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Table 2. Comparison of Tumor Characteristics at Baseline and Post-Radioembolization* 
Characteristics Baseline 
Post-
Radioembolization 
p Value
∞ 
Number of lesions
+
, median 
(range) 
3 (1 to 11) 4 (1 to 11) 0.313 
Tumor nodules, no. (%) 
< 5 
> 5 
 
7 (53.8) 
6 (46.2) 
 
7 (53.8) 
6 (46.2) 
0.029 
Tumor size, longest axis, mm,  
median (range) 
66.0 (15.0 to 99.0) 56.0 (19.0 to 121.0) 0.073 
Tumor size, perpendicular 
axis, mm,  median (range) 
54.0 (15.0 to 89.0) 44.0 (15.0 to 92.0) 0.046 
Tumor attenuation, HU, 
median (range) 
84.0 (0 to 133.0) 78.0 (0 to 127.0) 0.092 
Vascularity pattern, no. (%) 
Hyper 
Hypo 
 
12 (92.3) 
1 (7.7) 
 
10 (76.9) 
3 (23.1) 
0.231 
Necrosis, no. (%) 
< 50% 
> 50% 
 
12 (92.3) 
1 (7.7) 
 
10 (76.9) 
3 (23.1) 
0.231 
Presence of ascites, no. (%) 1 (7.7) 1 (7.7) 0.077 
Presence of PVT, no. (%) 10 (76.9) 12 (92.3) 0.231 
Abbreviations: PVT, portal vein thrombosis 
*N=13, 
+
  Two patients with innumerable lesions, 
∞
 Fisher exact and Wilcoxon rank test 
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Table 3. Survival by Baseline Characteristic* 
Characteristics 
Mean Survival 
(95% confidence interval) 
p Value 
All 37.5 (24.7,50.2) NA 
Age, years 
< 65 
> 65 
36.9 (7.4,51.6) 
27.0 (NA) 
 
0.921 
Gender 
Male 
Female 
36.8 (20.5,53.1) 
27.5(3.9,19.8)  
 
0.799 
Etiology 
HBV 
HCV 
Alcohol 
Other 
 
18.5 (17.8,19.2) 
28.7 (26.3,31.0) 
26.5 (9.2,43.8) 
50.8 (28.0,73.6) 
 
 
0.542 
Child-Pugh 
A 
B 
40.6 (25.5,55.7) 
23.3 (12.8,33.9)) 
 
0.381 
Albumin (g/L) 
≤ 35 
> 35 
44.7(26.4, 63.1) 
24.2 (15.9,32.4) 
 
0.095 
AFP (ng/mL) 
≤ 400 
> 400 
41.9 (26.9,57.1) 
29.5 (26.6,32.4) 
 
0.603 
ALT (U/L) 
≤ median 
> median 
30.7 (21.3,40.1) 
37.3 (22.6,52.1) 
 
0.903 
Total billirubin (mg/dL) 
≤ 1.5 
> 1.5 
27.6 (3.9,19.9) 
44.8 (26.4,63.1) 
 
0.285 
Number of treatments 
1 
2 
36.6 (19.9,53.4) 
30.4 (22.2,38.6) 
 
0.815 
Abbreviations: ALT, alanine aminotransferase; AFP, alpha-fetoprotein; NA, not applicable 
*N=16 
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Table 4. Survival by Imaging features at baseline* 
Characteristics 
Mean Survival 
(95% confidence interval) 
p Value 
Tumor burden 
≤ 5 
> 5 
32.6 (16.7,48.6) 
31.1 (22.2,39.9) 
 
0.447 
Tumor size, longest axis 
≤ median 
> median 
38.2 (18.4,58.0) 
27.4 (23.3,31.6) 
0.783 
Tumor margins 
Well 
Poor defined 
37.1 (20.8,53.2) 
27.0 (3.1,33.0)  
 
0.857 
Tumor attenuation, HU 
≤ median 
> median 
 
26.2 (21.0,31.5) 
42.3 (19.7,64.9) 
 
0.447 
Presence of PVT 
Yes 
No 
28.0 (20.0,36.0) 
35.6 (21.4,49.8) 
 
0.697 
Presence of Ascites 
Yes 
No 
31.0 (NA) 
39.0 (24.7,53.3) 
 
0.867 
Tumor enhancement 
Hypervascular 
Hypovascular 
41.9 (26.9,57.1) 
29.5 (26.6,32.4) 
 
0.603 
Abbreviations: ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PVT, portal vein 
thrombosis; NA, not applicable 
*N=16 
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Table 4. Survival by Response Criteria 
Response 
mRECIST EASL Choi 
No.(%) 
PR 3 (23.1) 
5 (38.5) 
5 (38.5) 
1 (7.7) 
7 (53.8) 
5 (31.3) 
NA Stable 
Progression 
Response 
NA 
9 (69.2) 
4 (30.8) No response 
p Value 0.765 0.428 0.930 
Abbreviations: PR, parcial response; NA, not applicable 
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